The presence of the IDH1 mutation could enhance GBM patient survival by increasing the production of the onco-metabolite (R)-2-hydroxyglutarate, which can induce genome-wide methylation alterations and alter cellular redox state to promote cellular transformation5,22. The gene discussed is IDH1; the disease is glioblastoma.